JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...